Yamada T, Morishita M, Yoshida K, Kinoshita S, Yokoi K, Nakamura M, Morita K, Harada T, Yagi S, Kitagawa S, Nakagawa M
Dept. of Surgery, Ishikawa Prefectural Central Hospital.
Gan To Kagaku Ryoho. 2001 Nov;28(12):1909-12.
TS-1 is a novel oral formation of 5-fluorouracil, developed using tegafur and two biochemical modulations. We report the case of a patient with multiple lymph node metastases from gastric cancer that markedly responded to TS-1. A 70-year-old man suffering from hematemesis was admitted to our hospital. Computed tomography showed advanced gastric cancer with huge lymph node metastases. After non-curative operation, he received adjuvant chemotherapy with TS-1 for 12 weeks. CT revealed that almost complete reduction of the metastatic nodes was obtained. No serious adverse reactions were observed.
TS-1是一种新型的5-氟尿嘧啶口服制剂，由替加氟和两种生化调节剂研制而成。我们报告了1例胃癌多发淋巴结转移患者对TS-1有显著反应的病例。一名70岁男性因呕血入院。计算机断层扫描显示进展期胃癌伴巨大淋巴结转移。在进行非根治性手术后，他接受了12周的TS-1辅助化疗。CT显示转移淋巴结几乎完全缩小。未观察到严重不良反应。
